SPECT imaging of GABAA/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 6, 2010, Pages 1156-1163

  Pappatà, Sabina ^a   Varrone, Andrea ^a   Vicidomini, Caterina ^a   Milan, Graziella ^b   De Falco, Caterina ^b   Sansone, Valeria ^a   Iavarone, Alessandro ^c   Comerci, Marco ^a   Loré, Elisa ^b   Panico, Maria Rosaria ^a   Quarantelli, Mario ^a   Postiglione, Alfredo ^b   Salvatore, Marco ^b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CTO Hospital   (Italy)

Author keywords

Alzheimer; Benzodiazepine receptors; Cerebral perfusion; Iomazenil; Mild cognitive impairment; SPECT

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; BENZODIAZEPINE RECEPTOR; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IOMAZENIL I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN PERFUSION; CELL LOSS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; LIMBIC CORTEX; MALE; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NERVE CELL; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPSE; VOXEL BASED MORPHOMETRY;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; FEMALE; FLUMAZENIL; HUMANS; MALE; MIDDLE AGED; RECEPTORS, GABA-A; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77954888295     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1409-1     Document Type: Article

References (31)

1. Pappatà S, Salvatore E, Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging 2008;18:111-24.
2. Rissman RA, De Blas AL, Armstrong DM. GABA (A) receptors in aging and Alzheimer's disease. J Neurochem 2007;103:1285-92.
3. Möhler H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J Neurochem 2007;102:1-12.
4. Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioral and psychological symptoms of dementia. Can J Psychiatry 2004;49:439-53.
5. Louzada PR, Paula Lima AC, Mendonca-Silva DL, Noël F, De Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of betaamyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 2004;18:511-8.
6. Rissman RA, Bennett DA, Armstrong DM. Subregional analysis of GABA (A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment. J Chem Neuroanat 2004;28:17-25.
7. Soricelli A, Postiglione A, Grivet-Fojaja MR, Mainenti PP, Discepolo A, Varrone A, et al. Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses. Eur J Nucl Med 1996;23:1323-8.
8. Fukuchi K, Hashikawa K, Seike Y, Moriwaki H, Oku N, Ishida M, et al. Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease. J Nucl Med 1997;38:467-70.
9. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995;52:314-7.
10. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, et al. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999;13:309-15.
11. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
12. Millet P, Graf C, Buck A, Walder B, Westera G, Broggini C, et al. Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors. J Cereb Blood Flow Metab 2000;20:1587-603.
13. Greenamyre JT, Penney JB, D'Amato CJ, Young AB. Dementia of the Alzheimer's type: changes in hippocampal L-[3H]glutamate binding. J Neurochem 1987;48:543-51.
14. Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 1990;39:613-27.
15. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988;23:404-6.
16. Cross AJ, Crow TJ, Ferrier IN, Johnson JA. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging 1986;7:3-7.
17. Owen F, Poulter M, Waddington JL, Mashal RD, Crow TJ. [3H]R05-4864 and [3H]flunitrazepam binding in kainatelesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res 1983;278:373-5.
18. Chu DC, Penney Jr JB, Young AB. Cortical GABAB and GABAA receptors in Alzheimer's disease: a quantitative autoradiographic study. Neurology 1987;37:1454-9.
19. Lloyd GK, Lowenthal A, Javoy-Agid F, Constantidinis J. GABAA receptor complex function in frontal cortex membranes from control and neurological patients. Eur J Pharmacol 1991;197:33-9.
20. Vogt BA, Crino PB, Volicer L. Laminar alterations in gammaaminobutyric acidA, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J Neurochem 1991;57:282-90.
21. Howell O, Atack JR, Dewar D, McKernan RM, Sur C. Density and pharmacology of alpha5 subunit-containing GABA (A) receptors are preserved in hippocampus of Alzheimer's disease patients. Neuroscience 2000;98:669-75.
22. Mizukami K, Ikonomovic MD, Grayson DR, et al. Immunohistochemical study of GABAA receptor alpha1 subunit in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Brain Res 1998;799:148-55.
23. Penney JB, Maragos WF, Greenamyre JT, Debowey DL, Hollingsworth Z, Young AB. Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. J Neurol Neurosurg Psychiatry 1990;53:314-20.
24. Hof PR, Cox K, Young WG, Celio MR, Rogers J, Morrison JH. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer's disease. J Neuropathol Exp Neurol 1991;50:451-62.
25. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395-402.
26. Bell KF, Claudio Cuello A. Altered synaptic function in Alzheimer's disease. Eur J Pharmacol 2006;545:11-21.
27. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007;55:697-711.
28. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-55.
29. Truchot L, Costes SN, Zimmer L, Laurent B, Le Bars D, Thomas-Antérion C, et al. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 2007;69:1012-7.
30. Borroni B, Anchisi D, Paghera B, et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 2006;27:24-31.
31. Chetelat G, Desgranges B, de la Sayette V, Viader F, Berkouk K, Landeau B, et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003;126:1955-67.